Helps keep you in range, day and night1,2
No multiple daily injections, tubes, or fingersticks*
Cleared for people with type 1 diabetes ages 2 years and older
The best of both worlds.
No need to compromise.
Long gone are the days of choosing between glucose results from an Automated Insulin Delivery System and freedom of a tubeless device. With Omnipod 5, you can have the best of both worlds, all in one.
More time in range
Clinical study participants showed improved time in range by 3.7 hours per day in children (2.6 hours per day in children ages 2-5.9 years) and 2.2 hours per day in adolescents and adults.1,2
Lower A1C
Clinical study participants experienced a reduction in A1C of 0.71% in children (0.5% in children ages 2-5.9 years) and 0.38% in adolescents and adults.1,2
Adapted to you
Omnipod 5 adapts with every Pod change to meet your unique insulin needs and adjusts insulin using a customized Target Glucose, not a range.
In a 3-month clinical study, 3 cases of severe hypoglycemia and 1 case of diabetic ketoacidosis (DKA) were reported in children and adults/adolescents during Omnipod 5 System use. These cases were not related to automated insulin delivery malfunction.
Innovation at your fingertips
Omnipod 5 boasts outstanding design and engineering, recognized by the CES Innovation Awards in 2022.
Using SmartAdjust™ technology, the Pod and Dexcom G6 CGM are in constant communication, enabling automatic insulin adjustments to help improve time in range.1,2 And, you can control it all from your fingertips with the Omnipod 5 App on a compatible smartphone.†
Always adjusting so you don’t have to
Omnipod 5 automatically increases, decreases, or pauses insulin delivery every 5 minutes, helping to protect against highs and lows, day and night.1,2
Hear real stories
“Having control over my diabetes and my numbers—I’ve found this new confidence that I didn’t have before.”
Morgan M.
Omnipod 5 User
Get started today – no contracts or commitments.
Omnipod 5 is available exclusively through the pharmacy channel, which means you can make the switch from multiple daily injections, a tubed pump, or another Omnipod System at any time. Simply fill out the form to get started.
Check Your Coverage for Omnipod® Products*
Get started today with a commitment free benefits check. Our Omnipod pharmacy support team† will check your coverage‡ for the Omnipod® 5 System and Omnipod DASH®, so you can see all your options. Never tried Omnipod® before? You may also qualify for our free trial program, depending on your insurance coverage and eligibility‡.
Here's how it works:
- Fill out the form below to get started
- Once complete, we will reach out to your doctor for a prescription to check your coverage and get back to you within 4-6 business days
*Available products subject to current insurance coverage and product indication for use. Insulet can only support onboarding for those customers within the product indication. The Omnipod® 5 System is currently indicated for use by individuals with type 1 diabetes, 2 years of age and older. Omnipod DASH® is currently indicated for all insulin-requiring users.
†ASPN Pharmacies and its dedicated staff power the Omnipod Pharmacy Support Program. The ASPN team is here for you to check your coverage and help coordinate fulfillment at your pharmacy of choice.
1. Study in 80 people with T1D aged 2 - 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 = 57.2% vs. 68.1%. Average time in Target Glucose range (12AM -< 6AM) from CGM in standard therapy vs. Omnipod 5 = 58.2% vs 81.0%. Average A1c in standard therapy vs. Omnipod 5 = 7.4% vs. 6.9%. Median time with low blood glucose from CGM: standard therapy = 3.43% vs. 2.46%. Sherr JL, et al. Diabetes Care (2022).
2. Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average day time (6AM-12AM) in Target Glucose range (from CGM) in adults/adolescents and children for standard therapy vs Omnipod 5 = 64.8% vs. 72.5%; 51.5% vs. 64.6%. Average overnight (12AM-6AM) in Target Glucose range (from CGM) in adults/adolescents and children for standard therapy vs Omnipod 5 = 64.3% vs. 78.1%; 55.3% vs. 78.1%. Brown et al. Diabetes Care (2021).
Risk Statement
The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires a prescription. The Omnipod 5 System is compatible with the following U-100 insulins: NovoRapid®, Humalog®, and Admelog®.The Omnipod 5 Pump (Pod) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The Omnipod 5 Pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. SmartAdjust™ technology is intended for use with compatible integrated continuous glucose monitors (iCGM) and to automatically increase, decrease, and pause delivery of insulin based on current and predicted glucose values. The Omnipod 5 SmartBolus Calculator is intended to calculate a suggested bolus dose based on user-entered carbohydrates, most recent sensor glucose value (or blood glucose reading if using fingerstick), rate of change of the sensor glucose (if applicable), insulin on board (IOB), and programmable correction factor, insulin to carbohydrate ratio, and target glucose value.
WARNING: SmartAdjust technology should NOT be used by anyone under the age of 2 years old. SmartAdjust technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population.The Omnipod 5 System is NOT recommended for people who are unable to monitor glucose as recommended by their healthcare provider, are unable to maintain contact with their healthcare provider, are unable to use the Omnipod 5 System according to instructions, are taking hydroxyurea as it could lead to falsely elevated CGM values and result in over-delivery of insulin that can lead to severe hypoglycemia, and do NOT have adequate hearing and/or vision to allow recognition of all functions of the Omnipod 5 System, including alerts, alarms, and reminders. Device components including the Pod, CGM transmitter, and CGM sensor must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components. Visit www.omnipod.com/safety for additional important safety information.
WARNING: DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia. The OmnipodPromise™ allows users to start on Omnipod DASH through the pharmacy and upgrade to any future Omnipod technology for no additional cost, when covered by insurance. The OmnipodPromise™ is only available for users with valid prescription and coverage through their pharmacy benefit. Upgrades subject to user's insurance coverage and product cost is subject to copays as required by insurance coverage.